S. Pancholi

发表

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

M. Dowsett, S. Johnston, C. Hilmi, 2008, Endocrine-related cancer.

ERBB 2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS 6 KA 2

M. Dowsett, S. Johnston, C. Hilmi, 2008 .

ESR 1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6 q 25 . 1

Mitch Dowsett, Helen Anderson, M. Dowsett, 2012 .

ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1

Mitch Dowsett, Helen Anderson, M. Dowsett, 2011, PLoS genetics.

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities

M. Dowsett, S. Johnston, A. Ressa, 2020, Oncogene.

The farnesyltransferase inhibitor R 115777 ( tipifarnib ) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo

M. Dowsett, J. Salter, E. Quinn, 2007 .

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance

M. Dowsett, S. Johnston, A. Lykkesfeldt, 2010, Clinical Cancer Research.

Amino acid depletion modulates vascular endothelial growth factor production during the life span of human vascular smooth muscle cells

K. Earle, S. Pancholi, J. Yudkin, 1998, Journal of cellular physiology.

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

Jeff S. Jasper, M. Dowsett, G. Crawford, 2019, Cell reports.

An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition

M. Dowsett, S. Johnston, Z. Ghazoui, 2011, Steroids.

Pattern of angiogenic cytokine release from human vascular smooth muscle cells programmed by amino acid deprivation.

K. Earle, S. Pancholi, 2000, Cytokine.

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy

M. Dowsett, S. Pancholi, D. Evans, 2010, British Journal of Cancer.

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

M. Dowsett, S. Château-Joubert, L. Zabaglo, 2019, Breast Cancer Research.

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

M. Dowsett, S. Johnston, T. Bihani, 2022, npj Breast Cancer.

The effects of growth factors and conditioned media on the proliferation of human corneal epithelial cells and keratocytes

M. Boulton, S. Pancholi, D. Foreman, 1996, Graefe's Archive for Clinical and Experimental Ophthalmology.

and conditioned media on the proliferation

M. Boulton, S. Pancholi, D. Foreman, 1998 .

A simple organ culture model for assessing the effects of growth factors on corneal re-epithelialization.

D McLeod, M. Boulton, S. Pancholi, 1996, Experimental eye research.

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

M. Dowsett, Z. Ghazoui, S. Pancholi, 2012, Breast Cancer Research.

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

M. Dowsett, J. Baselga, V. Serra, 2016, Cancer research.

Detection of ESR1 Mutations in Single Circulating Tumor Cells upon Estrogen Deprivation Therapy but not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.

P. Fasching, T. Fehm, I. Esposito, 2019, The Journal of molecular diagnostics : JMD.

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance

A. Vincent-Salomon, S. Vacher, A. Nicolas, 2020, Nature Communications.

GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.

M. Zvelebil, M. Dowsett, I. Plaza-Menacho, 2013, Cancer research.

3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer

Gerard P. Quinn, M. Cheang, A. Tutt, 2021, Cancer Research.

The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.

I Farmer, M. Dowsett, S. Pancholi, 2005, Endocrine-related cancer.

Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation

M. Dowsett, S. Johnston, S. Pancholi, 2016, PloS one.

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

M. Dowsett, I. Plaza-Menacho, C. Isacke, 2010, Oncogene.

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

M. Dowsett, S. Johnston, E. Schuster, 2018, Breast Cancer Research.

The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo

M. Dowsett, J. Salter, E. Quinn, 2007, Molecular Cancer Therapeutics.

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

M. Dowsett, S. Johnston, I. Smith, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90RSK in tamoxifen-resistant MCF-7 cells

M. Dowsett, S. Pancholi, L.-A. Martin, 2005, Breast Cancer Research.

Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo

M. Dowsett, H. Lane, S. Johnston, 2012, Breast Cancer Research.

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer

M. Zvelebil, M. Dowsett, A. Thompson, 2016, Breast Cancer Research.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance

Steffi Oesterreich, Simak Ali, Jason Carroll, 2017, Nature Communications.

ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942

Simak Ali, G. Sava, L. Buluwela, 2019, Oncogene.

Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.

M. Hao, M. Warmuth, B. Caleb, 2018, Cancer discovery.

The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer

M. Dowsett, Z. Ghazoui, I. Smith, 2008, Clinical Cancer Research.

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers

Mitch Dowsett, M. Dowsett, Z. Ghazoui, 2014, Breast Cancer Research.

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance

M. Dowsett, Simak Ali, J. Carroll, 2017, Nature Communications.

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo

M. Dowsett, S. Johnston, B. Davies, 2015, Molecular Cancer Therapeutics.

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease

M. Dowsett, S. Johnston, S. Pancholi, 2018, British Journal of Cancer.

The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling

M. Dowsett, S. Pancholi, L.-A. Martin, 2005, Breast Cancer Research.

AKT Antagonist AZD 5363 In fl uences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant ( ICI 182780 ) In Vivo

M. Dowsett, S. Johnston, B. Davies, 2015 .

Abstract P3-03-09: Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome

M. Dowsett, S. Johnston, S. Pancholi, 2017 .